Bukwang receives marketing approval in the Philippines

Bukwang Pharm says the Philippines health authorities have recently granted its market approval to clevudine, an oral, once-daily pyrimidine nucleoside analog that was previously evaluated in 14 clinical trials in more than 800 individuals.

Under the agreement with Bukwang, the Japanese drug maker Eisai is expected to market clevudine in the Philippines in June.

Clevudine is an antiviral ...